Gast ::
| Hauptseite > Workflowsammlungen > Publikationsgebühren > Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer’s Mice with Full-blown Pathology > print |
| Hauptseite > Workflowsammlungen > Publikationsgebühren > Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer’s Mice with Full-blown Pathology > print |
| 001 | 850919 | ||
| 005 | 20220930130154.0 | ||
| 024 | 7 | _ | |a 10.1007/s12035-018-1209-3 |2 doi |
| 024 | 7 | _ | |a 0893-7648 |2 ISSN |
| 024 | 7 | _ | |a 1559-1182 |2 ISSN |
| 024 | 7 | _ | |a 2128/21947 |2 Handle |
| 024 | 7 | _ | |a pmid:30003517 |2 pmid |
| 024 | 7 | _ | |a WOS:000460163700049 |2 WOS |
| 024 | 7 | _ | |a altmetric:45295266 |2 altmetric |
| 037 | _ | _ | |a FZJ-2018-04653 |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Schemmert, Sarah |0 P:(DE-Juel1)165908 |b 0 |u fzj |
| 245 | _ | _ | |a Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer’s Mice with Full-blown Pathology |
| 260 | _ | _ | |a Totowa, NJ |c 2019 |b Humana Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1553882314_25990 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Oligomers of the amyloid-β (Aβ) protein are suspected to be responsible for the development and progression of Alzheimer’s disease. Thus, the development of compounds that are able to eliminate already formed toxic Aβ oligomers is very desirable. Here, we describe the in vivo efficacy of the compound RD2, which was developed to directly and specifically eliminate toxic Aβ oligomers. In a truly therapeutic, rather than a preventive study, oral treatment with RD2 was able to reverse cognitive deficits and significantly reduce Aβ pathology in old-aged transgenic Alzheimer’s Disease mice with full-blown pathology and behavioral deficits. For the first time, we demonstrate the in vivo target engagement of RD2 by showing a significant reduction of Aβ oligomers in the brains of RD2-treated mice compared to placebo-treated mice. The correlation of Aβ elimination in vivo and the reversal of cognitive deficits in old-aged transgenic mice support the hypothesis that Aβ oligomers are relevant not only for disease development and progression, but also offer a promising target for the causal treatment of Alzheimer’s disease. |
| 536 | _ | _ | |a 553 - Physical Basis of Diseases (POF3-553) |0 G:(DE-HGF)POF3-553 |c POF3-553 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Schartmann, Elena |0 P:(DE-Juel1)166069 |b 1 |
| 700 | 1 | _ | |a Zafiu, Christian |0 P:(DE-Juel1)162137 |b 2 |u fzj |
| 700 | 1 | _ | |a Kass, Bettina |0 P:(DE-Juel1)171532 |b 3 |u fzj |
| 700 | 1 | _ | |a Hartwig, Sonja |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Lehr, Stefan |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Bannach, Oliver |0 P:(DE-Juel1)157832 |b 6 |u fzj |
| 700 | 1 | _ | |a Langen, Karl-Josef |0 P:(DE-Juel1)131777 |b 7 |u fzj |
| 700 | 1 | _ | |a Shah, Nadim Joni |0 P:(DE-Juel1)131794 |b 8 |u fzj |
| 700 | 1 | _ | |a Kutzsche, Janine |0 P:(DE-Juel1)159137 |b 9 |u fzj |
| 700 | 1 | _ | |a Willuweit, Antje |0 P:(DE-Juel1)144347 |b 10 |e Corresponding author |u fzj |
| 700 | 1 | _ | |a Willbold, Dieter |0 P:(DE-Juel1)132029 |b 11 |e Corresponding author |
| 773 | _ | _ | |a 10.1007/s12035-018-1209-3 |0 PERI:(DE-600)2079384-4 |n 3 |p 2211-2223 |t Molecular neurobiology |v 56 |y 2019 |x 0893-7648 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/850919/files/2936122539%20%28002%29.pdf |
| 856 | 4 | _ | |x icon |u https://juser.fz-juelich.de/record/850919/files/2936122539%20%28002%29.gif?subformat=icon |
| 856 | 4 | _ | |x icon-1440 |u https://juser.fz-juelich.de/record/850919/files/2936122539%20%28002%29.jpg?subformat=icon-1440 |
| 856 | 4 | _ | |x icon-180 |u https://juser.fz-juelich.de/record/850919/files/2936122539%20%28002%29.jpg?subformat=icon-180 |
| 856 | 4 | _ | |x icon-640 |u https://juser.fz-juelich.de/record/850919/files/2936122539%20%28002%29.jpg?subformat=icon-640 |
| 856 | 4 | _ | |x pdfa |u https://juser.fz-juelich.de/record/850919/files/2936122539%20%28002%29.pdf?subformat=pdfa |
| 856 | 4 | _ | |y OpenAccess |u https://juser.fz-juelich.de/record/850919/files/Schemmert2018_Article_A%CE%B2OligomerEliminationRestoresC.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://juser.fz-juelich.de/record/850919/files/Schemmert2018_Article_A%CE%B2OligomerEliminationRestoresC.pdf?subformat=pdfa |
| 909 | C | O | |o oai:juser.fz-juelich.de:850919 |p openaire |p open_access |p OpenAPC |p driver |p VDB |p openCost |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)165908 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)162137 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)171532 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)157832 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)131777 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)131794 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)159137 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 10 |6 P:(DE-Juel1)144347 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 11 |6 P:(DE-Juel1)132029 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences |1 G:(DE-HGF)POF3-550 |0 G:(DE-HGF)POF3-553 |2 G:(DE-HGF)POF3-500 |v Physical Basis of Diseases |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOL NEUROBIOL : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MOL NEUROBIOL : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)ICS-6-20110106 |k ICS-6 |l Strukturbiochemie |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 1 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-11-20170113 |k INM-11 |l Jara-Institut Quantum Information |x 2 |
| 920 | 1 | _ | |0 I:(DE-82)080010_20140620 |k JARA-BRAIN |l JARA-BRAIN |x 3 |
| 980 | 1 | _ | |a APC |
| 980 | 1 | _ | |a FullTexts |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-11-20170113 |
| 980 | _ | _ | |a I:(DE-82)080010_20140620 |
| 980 | _ | _ | |a APC |
| 981 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|